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Abstract
Background: The phosphate ester PR-104 is rapidly converted in vivo to the alcohol PR-104A, a nitrogen mustard
prodrug that is metabolised to hydroxylamine (PR-104H) and amine (PR-104M) DNA crosslinking agents by one-
electron reductases in hypoxic cells and by aldo-keto reductase 1C3 independently of oxygen. In a previous phase
I study using a q 3 week schedule of PR-104, the maximum tolerated dose (MTD) was 1100 mg/m
2 and fatigue,
neutropenic fever and infection were dose-limiting. The primary objective of the current study was to determine
the dose-limiting toxicity (DLT) and MTD of weekly PR-104.
Methods: Patients with advanced solid tumours received PR-104 as a 1-hour intravenous infusion on days 1, 8 and
15 every 28 days with assessment of pharmacokinetics on cycle 1 day 1. Twenty-six patients (pts) were enrolled (16
male/10 female; median age 58 yrs, range 30 to 70 yrs) who had received a median of two prior chemotherapy
regimens (range, 0 to 3) for melanoma (8 pts), colorectal or anal cancer (3 pts), NSCLC (3 pts), sarcoma (3 pts),
glioblastoma (2 pts), salivary gland tumours (2 pts) or other solid tumours (5 pts). PR-104 was administered at 135
mg/m
2 (3 pts), 270 mg/m
2 (6 pts), 540 mg/m
2 (6 pts), 675 mg/m
2 (7 pts) and 900 mg/m
2 (4 pts) for a median of
two treatment cycles (range, 1 to 7 cycles) and five infusions (range, 1 to 18) per patient.
Results: Dose-limiting toxicities (DLTs) during cycle one included grade four thrombocytopenia at 540 mg/m
2 (1 of
6 pts) and grade four thrombocytopenia and neutropenia at 900 mg/m
2 (2 of 4 pts). At an intermediate dose of
675 mg/m
2, there were no DLTs among a total of seven patients given 12 treatment cycles but all experienced
moderate to severe (grade 2 to 4) haematological toxicity. Thrombocytopenia was delayed in its onset and nadir,
and its recovery was protracted and incomplete in many patients. There were no complete or partial tumour
responses. PR-104-induced thrombocytopenia and neutropenia correlated with plasma AUC of PR-104, PR-104A
and an oxidative semi-mustard metabolite (PR-104S1), but no more strongly than with PR-104 dose-level. There
was no significant correlation between plasma AUC for the reduced metabolites and myelotoxicity.
Conclusions: Thrombocytopenia, and to a lesser extent neutropenia, was the DLT of weekly PR-104. The MTD was
675 mg/m
2/week. PR-104 given weekly may be a suitable protocol for further clinical evaluation as a short course
of treatment with fractionated radiotherapy or haematopoietic stem cell support, as its duration of dosing is
restricted by delayed-onset and protracted thrombocytopenia.
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PR-104 is a phosphate ester dinitrobenzamide mustard
pre-prodrug that is rapidly hydrolyzed systemically to
PR-104A, a bioreductive prodrug. PR-104A is in turn
activated via reduction by NADPH:cytochrome P450
oxidoreductase and other one-electron reductases in
hypoxic cells, and by aldo-keto reductase 1C3 (AKR1C3)
independently of oxygen, to the corresponding hydroxy-
lamine (PR-104H) and amine (PR-104M) metabolites.
Subsequently, these reactive nitrogen mustards crosslink
DNA and cause cytotoxicity in cells [1-5]. Hypoxia is a
common feature of many solid tumours and is asso-
ciated with poor prognosis and resistance to conven-
tional radiotherapy and chemotherapy [5-8]. In addition,
AKR1C3 has been shown to be up-regulated in several
types of human cancer [3,9-11]. Targeting ACK1C3 and
hypoxia in tumours is therefore a novel and promising
approach to cancer therapy.
PR-104 is known to have preclinical antitumour activ-
ity in human tumour xenograft models as mono-therapy
and in combination with radiotherapy and chemother-
apy [1,2,12]. In rats and dogs its dose-limiting toxicity
(DLT) was myelosuppression [13]. A previous phase I
study of PR-104 given as a 1-hour intravenous infusion
once every three weeks identified fatigue, neutropenic
sepsis and infection with normal neutrophil counts as
the DLTs and a maximum tolerated dose (MTD) of
1100 mg/m
2 3-weekly [13,14]. The current phase I study
of weekly PR-104 was undertaken to explore whether its
therapeutic index is related to the schedule of adminis-
tration. If so, then weekly administration may provide
higher dose-intensity and greater tumour activation of
PR-104, as well as being a schedule potentially suitable
for combination with fractionated radiotherapy or with
weekly chemotherapy. For this reason, we carried out
the phase I study we now report whose primary objec-
tive was to determine the MTD of intravenous PR-104
administered weekly in subjects with solid tumours. Sec-
ondary objectives included characterising the pharmaco-
kinetics of PR-104, PR-104A and its major metabolites
[15,16] and their relationship to toxicity, and assessing
evidence of anti-tumour activity.
Methods
Patient selection
Eligibility criteria for entry into this study included: age
18 years or more; histologically confirmed malignancy
for which no effective therapy existed; measurable or
evaluable disease; ECOG Performance Status of 0 or 1;
ability to provide written informed consent; no or stable
dose of systemic steroid for at least two weeks; adequate
bone marrow function (absolute neutrophil count ≥ 1.5
×1 0
9/L, platelet count ≥ 100 × 10
9/L, haemoglobin level
> 90 g/L not maintained by red blood cell transfusion,
prothrombin and activated partial thromboplastin times
< 1.1 × upper limit of normal (ULN)); adequate liver
function (serum bilirubin within normal limits, ALT and
AST < 2.5 × ULN), and serum creatinine < 1.5 × ULN.
Exclusion criteria included: licensed or investigational
anti-cancer therapy (including radiotherapy but exclud-
ing androgen deprivation therapy) within four weeks;
nitrosoureas or mitomycin C within 6 weeks; prior
radiotherapy to more than 25% of bone marrow; prior
high-dose chemotherapy; prior receipt of more than
three chemotherapy regimens; pregnancy, breast feeding
or plans for becoming pregnant during the study;
unwillingness to use effective contraception during the
s t u d ya n df o r3 0d a y sf o l l o w i n gt h el a s td o s eo fs t u d y
medication; other medical disorder or laboratory finding
that in the opinion of the investigator compromised
subject safety; less than four week since major surgery,
or; HIV, Hepatitis B surface Antigen or Hepatitis C
positivity with abnormal liver function tests.
Study design
This was a phase I, two-centre, open label, uncontrolled,
serial cohort, dose-escalation study evaluating weekly
intravenous administration of PR-104. Patients were
enrolled in serial cohorts of three patients each using a
conventional phase I study design to establish the MTD.
Recruitment to dose-levels was expanded if DLT was
observed.
Drug administration
A lyophilized cake of 400 mg of PR-104 was reconsti-
tuted in two mL of water for injection, further diluted
in 250 mL of 5% dextrose in water and administered as
an intravenous infusion over one hour on days 1, 8 and
15 of a 28 day treatment cycle. Prophylactic anti-emetics
were administered to all study patients. Other anticancer
treatments (except androgen deprivation therapy), pro-
phylactic haematopoietic growth factors and radiother-
apy were not permitted during the study.
Definition of DLT and MTD
Toxicity was assessed according to the National Cancer
Institute Common Toxicity Criteria for Adverse Events
(version 3.0). DLT was assessed during the first four
weeks following the start of PR-104 administration and
was defined as any one of the following: grade four
thrombocytopenia (platelets < 25 × 10
9/L) of any dura-
tion; other grade four haematological toxicity that lasted
for five days or more (haemoglobin < 65 g/L, neutro-
phils < 0.5 × 10
9/L); non-haematological toxicity ≥
grade three despite appropriate treatment; neutropenic
fever; grade two or higher neurotoxicity lasting one
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has not resolved within two weeks of the end of cycle
one (except grade two alopecia). The MTD was defined
as a dose level at which one or fewer subjects in six
exhibited DLT and for which the next highest dose level
demonstrated two or more of six subjects with DLT.
Starting dose and dose escalation scheme
T h es t a r t i n gd o s ew a s1 3 5m g / m
2 based on results of
toxicology studies in rats and dogs, of which the rat was
the most sensitive pre-clinical species to PR-104 (MTD
1328 and 2678 mg/m
2 in rats and dogs, respectively by
weekly dosing for 4 consecutive weeks). Five dose-levels
were explored: 135, 270, 540, 675 and 900 mg/m
2.
Dose-levels were escalated by 100% or less according to
the toxicity at preceding dose-levels after review of
safety data by the study safety committee.
Patient evaluation and follow-up
After gaining informed consent, baseline evaluations
included a history and physical examination, assessment
of performance status, complete blood count (CBC),
blood chemistry profile, coagulation studies (INR and
APPT), urinalysis, pregnancy test and serum tumour
markers. Vital signs and electrocardiogram were taken
before, during and after the administration of the first
dose of PR-104. With each cycle, weekly assessments
included performance status, symptom-directed physical
examination, laboratory investigations (CBC, coagulation
studies, serum chemistry and urinalysis), intercurrent
adverse events and concomitant medication use. Extent
of disease was determined by computed tomography or
magnetic resonance scans prior to enrolment and
repeated once every two treatment cycles. Efficacy was
assessed using Response Evaluation Criteria in Solid
Tumours (RECIST) criteria version 1.0 [17]. Where pos-
sible, complete blood counts data was collected after the
end of the study participation until death or commence-
ment of other cancer therapy.
Pharmacokinetic analyses
To evaluate the pharmacokinetics of PR-104, PR-104A
and their major metabolites, blood samples were col-
lected in EDTA vacutainer tubes pre-dose, 45 minutes
into the infusion, immediately following the completion
of the infusion and at 5, 10, 20, 30, 45, 60, 120, 240 min-
utes and 24 (±8) hours post-infusion of the first dose.
Blood samples were centrifuged for five minutes to pre-
pare plasma. Plasma was then immediately deproteinised
by addition of nine volumes of methanol:ammonium
acetate: acetic acid (1000:3.5:0.2 v/w/v) and stored at -70°
C. Extracts were assayed by validated ultra high-perfor-
mance liquid chromatography methods [18] using triple
quadrupole mass spectrometric detection with
tetradeuterated internal standards [19]. Non-compart-
mental pharmacokinetic analyses using WinNonLin
(v4.0.1), and actual infusion times and doses, was used to
derive the maximum plasma concentration (Cmax), area
under the plasma concentration time curve extrapolated
to infinity (AUC(0-inf)), clearance (Cl), volume of distribu-
tion at steady state (Vss) and elimination half-life (t1/2).
Statistics
Data were analysed using descriptive statistics including
the median, range and proportion, and mean and stan-
dard deviation for normally distributed data. Relation-
ships between dose-levels, pharmacokinetic parameters,
percentage change in platelet and neutrophil counts and
creatinine clearance were assessed by nonparametric
correlation analysis. A P < 0.05 was regarded as being
statistically significant.
Results
Patient characteristics and study treatment
This study enrolled a total of 26 adult cancer patients (16
males, 10 females), ranging in age from 30 to 70 years
(median, 58 years) with cancer diagnoses including mela-
noma (8 patients), colon, rectum or anus cancer (3
patients), non-small cell lung cancer (NSCLC) (3 patients),
sarcoma (3 patients), glioblastoma (2 patients), salivary
gland tumours (2 patients) or other tumour types (5
patients) (Table 1). All but four patients (15%) had received
prior chemotherapy. Cohorts of three to seven patients
were treated at one of five dose-levels (135, 270, 540, 675
and 900 mg/m
2) of PR-104 given by intravenous infusion
on days 1, 8 and 15 repeated every 28 days (Table 2).
Patients received a median of two treatment cycles (range,
1 to 7) and five infusions (range, 1 to 18) of PR-104.
MTD determination and DLTs
The MTD of weekly PR-104 was 675 mg/m
2 (Table 2).
Cycle one DLTs were experienced by two of four
patients (50%) receiving 900 mg/m
2,w h i c hw a so n e
dose-level higher than the MTD, and by one of six
patients (17%) receiving 540 mg/m
2,w h i c hw a so n e
dose-level lower than the MTD. One DLT was experi-
enced by a 44 year old male, with glioblastoma pre-
viously treated with two lines of chemotherapy, who
developed grade 4 neutropenia on day 14 of cycle one
of PR-104 900 mg/m
2 lasting greater than five days. A
second DLT occurred in a 66 year old female, with
NSCLC previously treated with two lines of cytotoxic
chemotherapy and with erlotinib, who developed grade
4 thrombocytopenia after going off-study for progressive
disease after a single infusion of PR-104 at 900 mg/m
2.
A third DLT occurred in a 55 year old male, with meta-
static melanoma previously treated with radiotherapy
and dacarbazine, who developed new cerebral
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him to go off-study after the first treatment cycle of PR-
104 at 540 mg/m
2. Twenty days later, he presented with
headache, vomiting, seizures and a platelet count of 22
×1 0
9/L. A CT scan showed intra-cerebral, subarachnoid
and intracranial tumour haemorrhage. The patient died
five days later despite supportive measures. At the inter-
mediate dose of 675 mg/m
2, there were no cycle one
DLTs in a total of seven patients.
Haematological toxicity
Haematological toxicity was the most significant type of
toxicity in this study. Of 26 patients treated with weekly
PR-104, 23 or 88% experienced some form of moderate
to severe haematological toxicity (grade ≥ 2) (Table 3),
and haematological toxicity DLTs defined the MTD, as
outlined above. Further occurrences of haematological
toxicity are outlined below, in Table 3, and in Figures 1
and 2.
Thrombocytopenia occurred in 14 of 26 patients
(54%) treated with weekly PR-104 and ranged from
grade 1 to 4 in severity (Table 3). The incidence of
moderately-severe or severe thrombocytopenia (grade 3
or 4) was 0, 33, 29 and 75% at the ≤ 270, 540, 675 and
900 mg/m
2 dose-levels, respectively. Onset of thrombo-
cytopenia was delayed by a median of six weeks (range
2 to 18 weeks), and thrombocytopenia nadirs by a med-
ian of ten weeks (range 5 to 19 weeks), relative to the
start of PR-104 treatment (Figure 1A-E). The maximum
percentage change in platelet count from baseline fol-
lowing the first treatment cycle correlated strongly with
PR-104 dose-level (Spearman r = -0.79; P =2×1 0
-7)
(Figure 1F). Platelet counts did not recover to baseline
levels in any patients who had experienced thrombocy-
topenia of any severity grade. Sustained recovery of pla-
telet counts to within normal limits occurred in only
two of 14 patients (14%) who had experienced thrombo-
cytopenia from PR-104. The duration of thrombocytope-
nia was correspondingly protracted and incompletely
defined (median, at least 7 weeks; range, 1 to at least 64
weeks), due to the persistence of this toxicity until the
death of study patients or their commencement of
further treatment, which confounded interpretation of
subsequent blood counts. Platelet transfusions were
required for severe thrombocytopenia and/or bleeding
by some patients but specific details were lacking
because data collection on blood product support data
was not part of the prospective study plan.
Neutropenia occurred in 11 of 26 patients (42%) and
ranged from grade 1 to 4 in severity (Table 3). Seven
patients had more than one episode of neutropenia
associated with repeated cycles of treatment. The inci-
dence of moderately-severe to severe neutropenia (grade
3 to 4) was 11, 17, 14 and 75% at the ≤ 270, 540, 675
and 900 mg/m
2 dose-levels, respectively. Onset of the
first episode of neutropenia occurred after a median of
Table 2 Dose escalation scheme, treatment delivery and cycle-one dose-limiting toxicity (DLTs)
Cohort
Number
Dose level
(mg/m2/wk)
Dose
increment
Number of
patients
Total number of cycles
(median per patient)
Total number of infusions
(median per patient)
Number of patients
with cycle-one DLT
1 135 - 3 9 (2) 32 (6) 0
2 270 100% 6 17 (2) 50 (6) 0
3 540 100% 6 11 (2) 30 (5) 1
a
4 675 25% 7 12 (2) 33 (5) 0
5 900 33% 4 6 (1.5) 15 (4) 2
b
agrade 4 thrombocytopenia;
bgrade 4 thrombocytopenia and grade 4 neutropenia lasting > 5 day
Table 1 Patient characteristics and previous
chemotherapy
Characteristic Number of patients (%)
Gender
Male 16 (62)
Female 10 (38)
Age (years)
Mean (range) 58 (30-70)
ECOG Performance Status
0 8 (31)
1 18 (69)
Tumour Type
Melanoma 8 (31)
Colon, rectum or anus 3 (12)
Non-small cell lung 3 (12)
Sarcoma 3 (12)
Glioblastoma 2 (8)
Salivary gland 2 (8)
Adrenal Cortex 1 (4)
Cervix 1 (4)
Head and neck 1 (4)
Kidney 1 (4)
Pancreas 1 (4)
Previous chemotherapy
No. of courses
None 4 (15)
One 8 (31)
Two 7 (27)
Three 7 (27)
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Page 4 of 12Table 3 Haematological toxicity
Worst toxicity severity grade of haematological toxicity by patient (number of patients (%))
Dose level 135 mg/m
2 270 mg/m
2 540 mg/m
2 675 mg/m
2 900 mg/m
2 All doses
Number of patients n = 3 n = 6 n = 6 n = 7 n = 4 n = 26
Toxicity severity grade 2 3 4 2 3 4 2 3423423 4 2 34
Anaemia 1 (33) 1 (33) 2 (33) 1 (17) 4 (67) 1 (17) 4 (57) 1 (14) 1 (14) 2 (50) 2 (50) 13 (50) 6 (23) 1 (14)
Leukopenia 1 (17) 2 (33) 1 (17) 3 (43) 2 (29) 2 (50) 1 (25) 8 (31) 4 (15)
Neutropenia 1 (17) 2 (33) 1 (17) 2 (29) 1 (14) 3 (75) 5 (19) 2 (8) 3 (12)
Thrombocytopenia 1 (17) 1 (17) 1 (17) 1 (17) 1 (14) 2 (29) 1 (25) 2 (50) 3 (12) 4 (15) 2 (8)
Any haematological toxicity 1 (33) 1 (33) 3 (50) 1 (17) 3 (50) 2 (33) 1 (17) 4 (57) 2 (29) 1 (14) 4 (100) 11 (42) 6 (23) 6 (23)
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Figure 1 PR-104-induced thrombocytopenia followed until death or further treatment. (a) Time-course of thrombocytopenia in each
subject at 135 mg/m
2 (b) Time-course of thrombocytopenia in each subject at 240 mg/m
2 (c) Time-course of thrombocytopenia in each subject
at 540 mg/m
2 (d) Time-course of thrombocytopenia in each subject at 675 mg/m
2 (e) Time-course of thrombocytopenia in each subject at 900
mg/m
2 (f) Platelet nadir on first treatment cycle correlated with PR-104 dose-level (Spearman r = -0.79; P <2×1 0
-7).
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Figure 2 PR-104-induced neutropenia followed until death or further treatment. (a) Time-course of neutropenia in each subject at 135
mg/m
2 (b) ime-course of neutropenia in each subject at 240 mg/m
2 (c) Time-course of neutropenia in each subject at 540 mg/m
2 (d) Time-
course of neutropenia in each subject at 675 mg/m
2 (e) Time-course of neutropenia in each subject at 900 mg/m
2 (f) Neutrophil nadir on first
treatment cycle correlated with PR-104 dose-level (Spearman r = -0.56; P < 0.005)
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Page 7 of 12three weeks (range 2 to 5 weeks), and nadirs of first epi-
sode of neutropenia occurred after a median of four
weeks (range 3 to 7 weeks), relative to the time of start-
ing PR-104 treatment (Figure 2A-E). Maximum percen-
tage change in neutrophil count from baseline following
the first treatment cycle correlated with PR-104 dose-
level (Spearman r = -0.56; P =0 . 0 0 5 )( F i g u r e2 F ) .T h e
duration of the first episode of neutropenia ranged from
one to 42 days (median 7 days). Subsequent episodes of
neutropenia tended to be more severe and longer lasting
than the initial occurrence especially when no dose
reductions or omissions were made for prior neutrope-
nia. Neutrophil counts recovered to baseline levels and/
or to within normal limits in all patients who had
experienced neutropenia from PR-104. There was one
uncomplicated episode of neutropenic sepsis.
Anaemia occurred in 24 of 26 patients (92%), ranged
from grade 1 to 4 in severity and was managed by red
cell transfusion. The incidence of moderately-severe or
severe anaemia (grade 3 or 4) was 30, 17, 17, 28 and
50% at the 135, 270, 540, 675 and 900 mg/m
2 dose-
levels, respectively. There was no correlation between
maximum percentage change in haemoglobin level from
baseline and PR-104 dose-level.
Non-haematological toxicity
Fatigue was the most common non-haematological toxi-
city that was considered related to PR-104 treatment
(Table 4). Gastrointestinal symptoms were reported by
about one quarter of patients but were self-limiting and
often considered unrelated to PR-104 treatment. Neither
were strongly related to dose level.
Tumour response
There were no complete or partial responses. Best
RECIST response category was progressive disease in 16
patients (61%), stable disease in eight patients (31%) and
non-evaluable in two patients (8%). A waterfall plot
showed that tumour dimensions increased during PR-
104 treatment in most patients (Figure 3). Two patients,
one each with soft tissue sarcoma (675 mg/m
2)and glio-
blastoma (900 mg/m
2), showed 22% reduction in
tumour burden from baseline but neither fulfilled
RECIST criteria for partial response.
Pharmacokinetics
Cmax and AUC values for PR-104 and PR-104A
increased in approximate proportion to respective dosage
increments between different dose-levels (Table 5), and
were linearly related to PR-104 dose-level (Figure 4). PR-
104 clearance was high (mean Cl, 107 L/h/m
2; CV, 70%).
PR-104 volume of distribution approximated total body
water (mean Vdss,3 5 . 8L / m
2;C V ,6 3 % ) .P R - 1 0 4h a l fl i f e
was short (mean t1/2,0 . 1 0h ;C V ,7 5 % ) ,w h i l eP R - 1 0 4 A
had a longer half life (mean t1/2,0 . 4 9h ;C V ,3 1 % ) .P K
parameters for the major plasma metabolites derived
from PR-104A (glucuronide PR-104G, reduced metabo-
lites PR-104H and PR-104M, and oxidative metabolite
PR-104S1) are shown in Table 6. Exposure (AUC) was
greatest for the glucuronide PR-104G, followed by hydro-
xylamine PR-104H, with lower AUC values for PR-104M
and PR-104S1. These metabolites had plasma half lives
comparable to PR-104A (mean t1/2 values 0.43, 0.61, 0.70
and 0.79 h respectively), suggesting that their clearance
may be rapid relative to the kinetics of their formation.
Plasma AUCs for PR-104, PR-104A and metabolites
Table 4 Non-haematological toxicity
Worst toxicity severity grade of non-haematological toxicity by patient (number of patients (%))
Toxicity severity grade 23 4
Fatigue 10 (38) 2 (8)
Abdominal pain 4 (15) 2 (8)
Constipation 7 (27)
Nausea 5 (19) 2 (8)
Back pain 3 (12) 2 (8)
Oedema peripheral 5 (19)
Vomiting 3 (12) 2 (8)
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Figure 3 Waterfall plot of maximum reduction in tumour
burden from baseline by dose level (135 mg/m
2 (white fill),
270 mg/m
2 (vertical lines), 540 mg/m
2 (diagonal lines), 675
mg/m
2 (horizonal lines) and 900 mg/m
2 (black fill)).
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Page 8 of 12appeared similar on cycle 1 day 1 to cycle 1 day 8 in three
patients who had pharmacokinetic studies on repeated
dosing at the MTD (675 mg/m
2)( T a b l e7 ) .O n ep a t i e n t
given naproxen, an inhibitor of AKR1C3 [20] and a sub-
strate for UGT2B7 [21], on cycle 2 day 1 (500 mg orally
two hours prior to PR-104) showed no apparent asso-
ciated change in the reduction or glucuronidation of PR-
104A compared to cycle 1 day 1.
Exposure to PR-104, PR-104A and PR-104G (AUC
values) correlated significantly with the severity of
thrombocytopenia and neutropenia (Table 8), although
the correlation coefficients were no higher than for the
relationships between toxicity and PR-104 dose. Notably,
the AUC for the cytotoxic reduced metabolites PR-104H
a n dP R - 1 0 4 M( c o m b i n e di nT a b l e8 )d i dn o tc o r r e l a t e
significantly with either thrombocytopenia or
neutropenia.
Discussion
We describe a phase I trial evaluating weekly adminis-
tration of PR-104, a novel nitrogen mustard pro-drug
activated by hypoxia and AKR1C3. Tumour hypoxia is
common in solid tumours and associated with poor
prognosis and resistance to radiotherapy and che-
motherapy [6-8]. AKR1C3 has been shown to be up-
regulated in some human cancers [9-11]. On this basis,
targeting tumour hypoxia and AKR1C3 is a promising
approach to cancer therapy.
In the current study, we determined the MTD of
weekly PR-104 to be 675 mg/m
2 given on days 1, 8 and
15 every 28 days. This MTD was established by the
occurrence of protocol-defined DLTs in one of six
( 1 7 % )o fp a t i e n t sa tt h e5 4 0m g / m
2 dose-level, and in
two of four (50%) of patients at the 900 mg/m
2 dose-
level. DLTs included two episodes of grade four throm-
bocytopenia, and a single episode of grade four neutro-
penia lasting greater than five days. In contrast, there
was no DLT at the MTD dose-level in a total of seven
patients given a total of 12 treatment cycles (median 2,
per patient) and 33 infusions (median, 5 per patient),
although all seven experienced moderate to severe
(grade 2 to 4) haematological toxicity. Thus, this study
met its primary objective of determining the DLT and
MTD of weekly PR-104.
Thrombocytopenia was the most significant clinical
toxicity associated with weekly PR-104 in this phase I
study. It was the major DLT and necessitated platelet
transfusions for very low counts and/or bleeding in
some patients but specific details of blood product sup-
port were not collected prospectively. The onset and
nadir of thrombocytopenia were delayed relative to the
commencement of PR-104 treatment by a median of six
and ten weeks, respectively. Thereafter, thrombocytope-
nia persisted without recovery to baseline or to normal
levels in most patients in whom it was feasible to under-
take longer term monitoring of platelet counts. Persist-
ing thrombocytopenia limited the delivery of weekly
treatment with PR-104 beyond two treatment cycles at
dose-levels of 540 mg/m
2 or more. The extent and sig-
nificance of protracted thrombocytopenia may have
been underestimated by this and previous studies of PR-
104 because of their use of definitions for DLTs con-
fined to adverse-events occurring within the first four
weeks of treatment, their lack of prospectively defined
plans for longer term monitoring of haematological toxi-
city and difficulties doing so in study populations with
short survival. In contrast, neutropenia was earlier in
onset and more reversible than thrombocytopenia but
also common and dose-limiting. Other toxicities
included anaemia, fatigue and gastrointestinal symptoms
but were less clinically significant and not dose-limiting.
One hypothesis for the mechanism underlying the
myelotoxicity of PR-104 is that the circulating reduced
metabolites (PR-104H and PR-104M), which are
Table 5 PR-104 and PR-104A plasma pharmacokinetic parameters for cycle 1 day 1
Cmax (μM) AUC (μM.h) t1/2 (h) Cl (L/h/m
2)V d ss (L/m
2)
Dose-level (mg/m
2) n PR-104 PR-104A PR-104 PR-104A PR-104 PR-104A PR-104 PR-104
135 2 4.08 3.49 2.85 3.22 0.06 0.34 128 38.7
270 6 7.63 (3.13) 6.81 (2.15) 4.15 (1.69) 6.61 (2.88) 0.07 (0.05) 0.42 (0.16) 129 (49.4) 39.1 (9.83)
540 6 14.2 (6.51) 13.7 (2.94) 9.34 (4.17) 14.0 (2.70) 0.07 (0.03) 0.42 (0.16) 130 (119) 44.7 (38.5)
675 7 18.1 (9.9) 15.5 (6.1) 12.9 (7.0) 17.7 (5.6) 0.14 (0.10) 0.55 (0.11) 92.7 (52.2) 27.3 (14.4)
900 4 20.8 (5.71) 23.3 (4.64) 15.2 (4.97) 29.5 (8.44) 0.15 (0.10) 0.68 (0.14) 64.8 (22.9) 24.2 (10.5)
Values are the mean (SD)
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Figure 4 Linear relationship between PR-104 dose-level and
PR-104 (A) and PR-104A exposure (B).
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Page 9 of 12activated nitrogen mustards, might be responsible. How-
ever, the lack of correlation between systemic exposure
to these metabolites and either neutropenia or thrombo-
cytopenia (Table 8) argues against this hypothesis. This
in turn suggests that myelotoxicity might result from
activation of PR-104A locally in the bone marrow, as a
result of expression of AKR1C3 in myeloid progenitor
cells [22] and/or hypoxia in bone marrow stem cell
niches as reported in mice [23].
The findings of this study suggest that treatment pro-
tocols for giving PR-104 at weekly intervals at or about
ad o s eo f6 7 5m g / m
2 may be feasible for a short course
of treatment only as the total duration of treatment
w o u l db er e s t r i c t e db yt o x i c ity. Continued treatment at
this dose-level beyond six to eight weeks may not be
feasible because of delayed onset thrombocytopenia that
would then persist, necessitating the deferral, reduction
or omission of subsequent PR-104 dosing. Single doses
of PR-104 of 675 mg/m
2 were shown by pharmacoki-
netic studies carried out on day one of cycle one in the
current study to achieve systemic exposures to PR-104A
ranging between 10.9 to 25.9 uM.hr. These PR-104A
AUC values were close to but lower than those (> 30
μM.hr) achieved in a previous phase I study of q 3
weekly dosing of PR-104 [14], and those associated with
preclinical activity of PR-104 in human tumour xeno-
graft models (> 30 μM.hr) [1,2,12]. Repeated dosing of
PR-104 at 675 mg/m
2 was shown to achieve cumulative
exposures to PR-104A exceeding these threshold levels
required for experimental activity, since a target AUC of
30 μM.hr or more was exceeded after two or three
doses (Table 7). In addition, reductions in tumour
dimensions of > 20% seen in two patients at > 540 mg/
m
2, and significant myelosuppression likely related to
the main pharmacological action of PR-104, provides
further supporting evidence for therapeutically active
exposures having been achieved on the phase I trial of
weekly treatment. Thus, treatment protocols for giving
PR-104 weekly at or about a dose of 675 mg/m
2 over 4
to 6 weeks may be suitable for future study to explore
its clinical feasibility and activity as a single agent or in
combination therapy.
Short courses of weekly PR-104 may be suitable for
use concurrently with fractionated radiotherapy or as
high-dose chemotherapy prior to bone marrow reconsti-
tution. Many conventional fractionated radiotherapy
regimens are limited by tumour hypoxia and given over
a short period of up to six weeks, to which it may be
feasible to add weekly PR-104. The delayed-onset
Table 6 Plasma pharmacokinetic parameters for PR-104A metabolites, cycle 1 day 1
Cmax (μM) AUC (μMh ) t 1/2 (h)
Dose-level (mg/
m
2)
n PR-104G PR-104H PR-
104M
PR-
104S1
PR-104G PR-104H PR-
104M
PR-
104S1
PR-104G PR-104H PR-
104M
PR-
104S1
135 2 1.66 0.66 0.05 0.06 1.67 0.79 0.08 0.10 0.25 0.48 0.53 0.76
270 6 3.02
(2.12)
0.68
(0.29)
0.06
(0.02)
0.14
(0.09)
3.96 (3.81) 0.81
(0.37)
0.11
(0.05)
0.25
(0.17)
0.40
(0.22)
0.51
(0.12)
0.88
(0.43)
1.09
(0.51)
540 6 11.27
(8.07)
0.49
(0.17)
0.07
(0.02)
0.20
(0.08)
13.85
(12.01)
0.63
(0.26)
0.11
(0.04)
0.29
(0.13)
0.38
(0.14)
0.41
(0.12)
0.56
(0.15)
0.59
(0.23)
675 7 8.71
(4.52)
0.51
(0.27)
0.08
(0.05)
0.36
(0.25)
11.9 (7.4) 0.71
(0.32)
0.13
(0.06)
0.49
(0.45)
0.49
(0.17)
0.74
(0.37)
0.75
(0.28)
0.68
(0.12)
900 4 7.81
(3.92)
0.39
(0.16)
0.07
(0.03)
0.31
(0.13)
11.19
(6.54)
0.69
(0.26)
0.16
(0.08)
0.64
(0.25)
0.68
(0.18)
0.85
(0.09)
0.88
(0.11)
0.79
(0.15)
Values are the mean (SD)
Table 7 Lack of change in plasma AUCs (μM.h) of PR-104,
PR-104A and metabolites with repeat dosing of PR-104
at 675 mg/m
2 on cycle 1 day 1 (C1D1), cycle 1 day 8
(C1D8) and cycle 2 day 1 (C2D1)
Patient Cycle PR-
104
PR-
104A
PR-
104G
PR-
104H
PR-
104M
PR-
104S1
04-75 C1D1 6.34 12.11 6.60 0.51 0.06 0.16
C1D8 6.61 13.16 7.74 0.44 0.09 0.16
01-76 C1D1 6.76 14.14 21.38 0.56 0.11 0.87
C1D8 7.91 16.72 28.01 0.45 0.10 1.09
04-77 C1D1 14.55 17.81 7.07 0.25 0.12 0.31
C1D8 11.01 16.96 7.53 0.26 0.12 0.36
C2D1* 8.16 19.53 6.73 0.59 0.10 0.44
*, given with naproxen.
Table 8 Correlations between drug exposure and toxicity,
normalised drug exposure and creatinine clearance
(Spearman rank order analysis).
Exposure platelets
† neutrophils
† CrCl
‡
Dose -0.79 (2 × 10
-7) -0.56 (5 × 10
-3)-
PR-104 AUC -0.56 (0.005) -0.35 (0.1) -0.14 (0.52)
PR-104A AUC -0.75 (2 × 10
-7) -0.49 (0.02) -0.12 (0.59)
PR-104G AUC -0.51 (0.01) -0.13 (0.56) -0.01 (0.98)
PR-104(H+M) AUC 0.09 (0.67) -0.04 (0.84) -0.04 (0.86)
PR-104S1 AUC -0.61 (0.002) -0.53 (0.009) -0.16 (0.46)
†At nadir (percentage of pretreatment value)
‡Creatinine clearance. Drug exposures (AUC) are normalised by dose levels.
Values are correlation coefficient and (p value).
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Page 10 of 12myelosuppresion of PR-104, combined with its minimal
non-haematological toxicity, may allow its delivery at or
beyond the current MTD prior to haematological stem
cell support via infusions of autologous bone marrow or
peripheral blood stem cells. It will be necessary however
to establish the feasibility of treatment protocols based
on weekly PR-104 combined with fractionated radiother-
apy and/or bone support in further early phase clinical
studies with careful longer term monitoring of haemato-
logical toxicity and provision of blood product support
as required. An exploratory study of PR-104 in relapsed
and treatment-refractory acute leukaemia is currently
underway (ClinicalTrials.gov Identifier: NCT01037556;
http://clinicaltrials.gov/ct2/show/NCT01358227?
term=pr104&rank=3) that is supported by evidence of
preclinical activity in this disease setting [24].
Conclusions
This study identified thrombocytopenia, and to a lesser
extent neutropenia, as the DLT of weekly PR-104, and
its MTD as 675 mg/m
2/week. Weekly PR-104 may be a
suitable administration schedule for further evaluation
as a short treatment course in combination with fractio-
nated radiotherapy or prior to haematopoietic stem cell
support.
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